Drug Profile
Research programme: autoimmune disorder and cancer therapeutics - Yuhan
Alternative Names: YH NCE2; YH NCE3Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antineoplastics; Antipsoriatics; Eye disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Graves ophthalmopathy; Liver cancer; Lung cancer; Psoriasis
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Liver-cancer in South Korea
- 28 May 2022 No recent reports of development identified for research development in Lung-cancer in South Korea
- 28 Feb 2020 No recent reports of development identified for preclinical development in Graves-ophthalmopathy in South Korea